News Releases

December 11, 2019

Vyriad Inc. Names Experienced Life Sciences Investors Edwin Kania and Nathan Stacy to its Board of Directors

November 6, 2019

Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer

July 28, 2018

Vyriad Announces Collaboration with Merck KGaA and Pfizer to Evaluate Oncolytic Virus, Voyager-V1, in Combination with Anti-PD-L1 Antibody, Avelumab, in Phase 1 Clinical Study for Metastatic Colorectal Cancer

May 10, 2018

Vyriad to Build State-of-the-Art Facility for Manufacturing Oncolytic Virus Anti-Cancer Vaccines in Rochester, Minn.

August 15, 2017

Clinical trial uses a genetically engineered virus to fight cancer

April 25, 2017

Tessa Therapeutics and Vyriad Form Partnership to Create Next Generation of Cancer Immunotherapy Treatments

August 16, 2016

Vyriad Announces Agreement with Imanis Life Sciences for Development of Theranostic Tests to Predict Responsiveness to Oncolytic Virotherapy

August 5, 2016

Vyriad Appoints Alice Bexon, MD, as Chief Medical Officer

August 5, 2016

Vyriad Signs Exclusive License Agreement for STING Technology for Development of Enhanced Oncolytic Virotherapy Treatments

March 18, 2016

Omnis Pharma and Magnis Therapeutics Merge to Form Vyriad, a Clinical-Stage Oncolytic Immunovirotherapy Development Company

March 18, 2016

Profectus and Vyriad Form Global Collaboration to Develop Oncolytic Recombinant VSV (rVSV) Vaccines for Cancer Immunotherapy